Pen Needles Market Size, Share & Trends Analysis Report By Product (Standard & Safety Pen Needles), By Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), By Therapy (Insulin, Glucagon-like-Peptide-1), Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global pen needles market size was exhibited at USD 3.40 billion in 2023 and is projected to hit around USD 10.47 billion by 2033, growing at a CAGR of 11.9% during the forecast period of 2024 to 2033.

Key Takeaways:

  • In 2023, Europe dominated the market with 40.0% share due to its rising prevalence of the target disease in this region.
  • In 2023, standard pen needles were identified as the largest segment with a commanding share of over 87.0%.
  • Amongst the various needle lengths, 8mm sized pen needle accounted for a lucrative market size in 2023
  • The insulin therapy segment dominated the market in 2023 with over 88.0% share and is also expected to showcase lucrative growth over the forecast period.

Pen Needles Market Report Scope

 Report Coverage  Details
Market Size in 2024 USD 3.40 Billion
Market Size by 2033 USD 10.47 Billion
Growth Rate From 2024 to 2033 CAGR of 11.9%
Base Year 2023
Forecast Period 2024-2033
Segments Covered Product, Needle Length, Therapy, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Novo Nordisk A/S; Becton Dickinson and Company; Terumo Corp.; Owen Mumford Ltd.; Ypsomed; B. Braun Melsungen AG; HTL-STREFA; UltiMed, Inc.; Allison Medical, Inc.; Artsana S.p.A.

 

The growing prevalence of diabetes has led to rising demand for pen needles. According to the International Diabetes Federation (IDF), 642 million people are estimated to have diabetes by 2040. With the rising population of diabetes, the target market is expected to grow at a lucrative rate over the forecast period.

Pen injectors are commonly used by diabetic patients for injecting insulin or any other medication. The obese population is highly susceptible to diabetes, and according to Diabetes.co.uk, obesity is assumed to account for 80-85% of the risk of developing diabetes. Insulin pens are the most convenient and fastest mode of injecting drug. Pen needles are highly demanded in conjunction with the growing need for insulin pens for people suffering from diabetes. These devices used with insulin pens help in delivering the dosage of the drug to the patient. 

Technological advancements in the different types of products are also anticipated to drive the growth of the pen needles industry. Companies are focusing on new product development with respect to needle length. For instance, In 2021, BD (Becton, Dickinson and Company) introduced the BD Nano Ultra-Fine pen needle, which has a 4 mm needle length for improved patient comfort and reliable insulin delivery. 

Insulin pens coupled with needles are considered as an improved alternative drug delivery process in comparison to syringes and vials. Traditional syringes are large and create difficulty in self-administration. However, pen needles have fine pointed tips, which helps in easy penetration into the patient’s muscle. These needles also facilitate safety pertaining to insulin delivery amongst diabetic patients.

Segments Insights:

Product Insights 

In 2023, standard pen needles were identified as the largest segment with a commanding share of over 87.0% due to its daily usage of larger dosage by diabetic patients. People suffering from dexterity problems commonly use these needles. However, these needles are not preferred since there is a high risk of causing needlestick injuries, which hampers the safe applicability of pen needles, hence, there demand is anticipated to go down over the forecast period. 

The rising number of diabetic population and awareness level regarding the usage of insulin pens are some of the factors supporting the growth of this segment. According to WHO, diabetes affects around 422 million people globally, with the vast majority residing in low- and middle-income countries. Also, it is directly responsible for 1.5 million fatalities per year. The prevalence and incidences of diabetes has been on a rise over the last decade.

Safety pen needles are expected to witness lucrative growth over the forecast period due to rising technological advancements in this field. These devices enable the minimization of needlestick injuries amongst patients. For instance, according to the National Library of Medicine, the majority of needlestick injuries (NSIs) are caused by faulty needles. A built-in sharps injury prevention function (SIPF) in safety pen needles (SPN) helps to prevent such injuries before, during, and after usage. 

Needle Length Insights 

Amongst the various needle lengths, 8mm sized pen needle accounted for a lucrative market size in 2023, generating over USD 629.0 million in the global market. These needles are most commonly prescribed to all patients including the overweight people suffering from the target disease. These needles are administered to most patients, including those with the target condition who are overweight. It offers advantages such as protection, user convenience, and ease of disposal. These needles are employed in home settings. Other variables, such as accessibility and cost, are projected to boost category expansion. The needles are less likely to cause a needlestick injury and are simple and safe to dispose of due to their larger size. 

Needle length of 4mm is anticipated to witness attractive CAGR over the forecast period owing to its short length. Shortest and thinnest needles are increasingly being used by patients due to a greater comfort level offered by them as compared to injections. Moreover, their short layer helps reach the subcutaneous tissue of the patients easily. According to recent studies, short-length needles are just as effective as their longer counterparts. People suffering from trypanophobia can simply use these needles. The use of 4mm and smaller needles helps to reduce intramuscular injection side effects and uneven dosages. 

Therapy Insights 

Based on therapy type, the pen needles market has been segmented into insulin, GLP-1, and growth hormone. The insulin therapy segment dominated the market in 2023 with over 88.0% share and is also expected to showcase lucrative growth over the forecast period. This is due to the increasing awareness about the self-administration of insulin therapy amongst type 1 and type 2 diabetes patients. For instance, Lilly's MounjaroTM (tirzepatide) injectable has been approved by the FDA as the first and only GIP and GLP-1 receptor agonist for the management of individuals with type 2 diabetes. GLP-1 therapy is also expected to exhibit significant growth in the near future. This is due to its capability to minimize the blood glucose level amongst patients suffering from type 2 diabetes. In addition, Novo Nordisk is also focusing on the expansion of GLP-1 market.

Dulaglutide, Exenatide (extended-release), and Semaglutide are some of the GLP-1 drugs that are taken once weekly. Along with blood sugar control, these help with weight loss, which is of high importance in diabetes patients. Growth hormone therapy includes injection either by traditional syringe-vial combination or injection pens. Owing to the complications and minimal user-friendliness of syringe-vial combination, it is getting rapidly replaced by injection pens. As most growth hormone deficiency patients are children, user acceptance is important in product development. Companies are focusing on pen needle development with minimum pain. Omnitrope is one of the leading brands of injection pens intended for growth hormone deficiency.

Regional Insights

In 2023, Europe dominated the market with 40% share due to its rising prevalence of the target disease in this region. Moreover, the U.K. government is also taking initiatives to invest in diabetes care and research to improve treatment techniques for diabetic patients. The growing number of diabetic patients in this region is essentially driving market expansion in U.K. For instance, according to Diabetes UK, Diabetes affects more than 4.3 million people in the U.K. Furthermore, 850,000 persons with diabetes may be living undiagnosed. 

Asia Pacific is projected to witness an attractive growth rate over the forecast period. Growing demand for pen needles over syringes and vials, as well as an increase in geriatric populations, are driving the APAC pen needles market. China is yet another prospective market in the Asia Pacific area. The growing number of diabetic patients in this region is essentially driving market expansion in China. For instance, the overall prevalence of diabetes among adults is currently at 11.2%, according to the Guidelines for the Prevention and Treatment of Diabetes in China (2020 Edition), and the number people with diabetes is estimated at 141 million, with an undiagnosed ratio of 51.7%.

Prevalence of diabetes, increasing rates of obesity and other lifestyle disorders are rising continuously and hence, the demand for the pen needles is anticipated to witness an attractive CAGR of over 13.8% in APAC over the forecast period. This is primarily due to the rising awareness about the availability of the latest technological devices for diabetes care. 

Some of the prominent players in the Pen needles market include:

  • Novo Nordisk A/S
  • Becton
  • Dickinson and Company
  • Terumo Corp.
  • Owen Mumford Ltd.
  • Ypsomed
  • B. Braun Melsungen AG
  • HTL-STREFA
  • UltiMed, Inc.
  • Allison Medical, Inc.
  • Artsana S.p.A.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global pen needles market.

Product

  • Standard Pen Needles
  • Safety Pen Needles

Needle Length

  • 4 mm
  • 5 mm
  • 6 mm
  • 8 mm
  • 10 mm
  • 12 mm

Therapy

  • Insulin
  • Glucagon-like-Peptide-1 (GLP-1)
  • Growth Hormone

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.1.1. Product

1.1.2. Needle Length

1.1.3. Therapy

1.1.4. Regional scope

1.1.5. Estimates and forecast timeline

1.2. Research Methodology

1.3. Information Procurement

1.3.1. Purchased database

1.3.2. internal database

1.3.3. Secondary sources

1.3.4. Primary research

1.3.5. Details of primary research

1.3.5.1. Data for primary interviews in North America

1.3.5.2. Data for primary interviews in Europe

1.3.5.3. Data for primary interviews in Asia Pacific

1.3.5.4. Data for primary interviews in Latin America

1.3.5.5. Data for Primary interviews in MEA

1.4. Information or Data Analysis

1.4.1. Data analysis models

1.5. Market Formulation & Validation

1.6. Model Details

1.6.1. Commodity flow analysis (Model 1)

1.6.1.1. Approach 1: Commodity flow approach

1.6.2. Volume price analysis (Model 2)

1.6.2.1. Approach 2: Volume price analysis

1.7. List of Secondary Sources

1.8. List of Primary Sources

1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot

2.2. Segment Snapshot

2.3. Competitive Snapshot

Chapter 3. Pen Needles Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Industry Value Chain Analysis

3.3.1. Reimbursement framework

3.4. Market Dynamics

3.4.1. Market driver analysis

3.4.1.1. Growing prevalence of diabetes

3.4.1.2. Technological advancements

3.4.2. Market restraint analysis

3.4.2.1. Preference for alternative drug delivery method

3.4.2.2. Lack of skilled professionals

3.5. Pen Needles Market Analysis Tools

3.5.1. Industry Analysis – Porter’s

3.5.1.1. Supplier power

3.5.1.2. Buyer power

3.5.1.3. Substitution threat

3.5.1.4. Threat of new entrant

3.5.1.5. Competitive rivalry

3.5.2. PESTEL Analysis

3.5.2.1. Political landscape

3.5.2.2. Technological landscape

3.5.2.3. Economic landscape

3.5.3. Major Deals & Strategic Alliances Analysis

3.5.4. Market Entry Strategies

Chapter 4. Pen Needles Market: Product Estimates & Trend Analysis

4.1. Definitions and Scope

4.1.1. Standard Pen Needles

4.1.2. Safety Pen Needles

4.2. Product Market Share, 2024 & 2033

4.3. Segment Dashboard

4.4. Global Pen Needles Market by Product Outlook

4.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following

4.5.1. Standard Pen Needles

4.5.1.1. Standard pen needles market estimates and forecast 2021 to 2033 (USD Million)

4.5.2. Safety Pen Needles

4.5.2.1. Safety pen needles market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Pen Needles Market: Needle Length Estimates & Trend Analysis

5.1. Definitions and Scope

5.1.1. 4mm

5.1.2. 5mm

5.1.3. 6mm

5.1.4. 8mm

5.1.5. 10mm

5.1.6. 12mm

5.2. Needle Length Market Share, 2024 & 2033

5.3. Segment Dashboard

5.4. Pen Needles Market by Needle Length Outlook

5.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following

5.5.1. 4mm

5.5.1.1. 4mm market estimates and forecast 2021 to 2033 (USD Million)

5.5.2. 5mm

5.5.2.1. 5mm market estimates and forecast 2021 to 2033 (USD Million)

5.5.3. 6mm

5.5.3.1. 6mm market estimates and forecast 2021 to 2033 (USD Million)

5.5.4. 8mm

5.5.4.1. 8mm market estimates and forecast 2021 to 2033 (USD Million)

5.5.5. 10mm

5.5.5.1. 10mm market estimates and forecast 2021 to 2033 (USD Million)

5.5.6. 12mm

5.5.6.1. 12mm market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Pen Needles Market: Therapy Estimates & Trend Analysis

6.1. Definitions and Scope

6.1.1. Insulin

6.1.2. Glucagon-like-peptide-1

6.1.3. Growth Harmone

6.2. Therapy Market Share, 2024 & 2033

6.3. Segment Dashboard

6.4. Pen Needles Market by Therapy Outlook

6.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following

6.5.1. Insulin

6.5.1.1. Insulin market estimates and forecast 2021 to 2033 (USD Million)

6.5.2. Glucagon-like-peptide-1

6.5.2.1. Glucagon-like-peptide-1 market estimates and forecast 2021 to 2033 (USD Million)

6.5.3. Growth Harmone

6.5.3.1. Growth harmone market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Pen Needles Market: Regional Estimates & Trend Analysis

7.1. Regional market share analysis, 2024 & 2033

7.2. Regional Market Dashboard

7.3. Global Regional Market Snapshot

7.4. Regional Market Share and Leading Players, 2024

7.4.1. North America

7.4.2. Europe

7.4.3. Asia Pacific

7.4.4. Latin America

7.4.5. Middle East and Africa

7.5. Market Application, & Forecasts and Trend Analysis, 2021 to 2033:

7.6. North America

7.6.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)

7.6.2. U.S.

7.6.2.1. Key country dynamics

7.6.2.2. Competitive Scenario

7.6.2.3. Regulatory framework

7.6.2.4. Reimbursement scenario

7.6.2.5. U.S. market estimates and forecasts, 2021 - 2033

7.6.3. Canada

7.6.3.1. Key country dynamics

7.6.3.2. Competitive Scenario

7.6.3.3. Regulatory framework

7.6.3.4. Reimbursement scenario

7.6.3.5. Canada market estimates and forecasts, 2021 - 2033

7.7. Europe

7.7.1. UK

7.7.1.1. Key country dynamics

7.7.1.2. Competitive Scenario

7.7.1.3. Regulatory framework

7.7.1.4. Reimbursement scenario

7.7.1.5. UK market estimates and forecasts, 2021 - 2033

7.7.2. Germany

7.7.2.1. Key country dynamics

7.7.2.2. Competitive Scenario

7.7.2.3. Regulatory framework

7.7.2.4. Reimbursement scenario

7.7.2.5. Germany market estimates and forecasts, 2021 - 2033

7.7.3. France

7.7.3.1. Key country dynamics

7.7.3.2. Competitive Scenario

7.7.3.3. Regulatory framework

7.7.3.4. Reimbursement scenario

7.7.3.5. France market estimates and forecasts, 2021 - 2033

7.7.4. Italy

7.7.4.1. Key country dynamics

7.7.4.2. Competitive Scenario

7.7.4.3. Regulatory framework

7.7.4.4. Reimbursement scenario

7.7.4.5. Italy market estimates and forecasts, 2021 - 2033

7.7.5. Spain

7.7.5.1. Key country dynamics

7.7.5.2. Competitive Scenario

7.7.5.3. Regulatory framework

7.7.5.4. Reimbursement scenario

7.7.5.5. Spain market estimates and forecasts, 2021 - 2033

7.7.6. Denmark

7.7.6.1. Key country dynamics

7.7.6.2. Competitive Scenario

7.7.6.3. Regulatory framework

7.7.6.4. Reimbursement scenario

7.7.6.5. Denmark market estimates and forecasts, 2021 - 2033

7.7.7. Sweden

7.7.7.1. Key country dynamics

7.7.7.2. Competitive Scenario

7.7.7.3. Regulatory framework

7.7.7.4. Reimbursement scenario

7.7.7.5. Sweden market estimates and forecasts, 2021 - 2033

7.7.8. Norway

7.7.8.1. Key country dynamics

7.7.8.2. Competitive Scenario

7.7.8.3. Regulatory framework

7.7.8.4. Reimbursement scenario

7.7.8.5. Norway market estimates and forecasts, 2021 - 2033

7.8. Asia Pacific

7.8.1. Japan

7.8.1.1. Key country dynamics

7.8.1.2. Competitive Scenario

7.8.1.3. Regulatory framework

7.8.1.4. Reimbursement scenario

7.8.1.5. Japan market estimates and forecasts, 2021 - 2033

7.8.2. India

7.8.2.1. Key country dynamics

7.8.2.2. Competitive Scenario

7.8.2.3. Regulatory framework

7.8.2.4. Reimbursement scenario

7.8.2.5. India market estimates and forecasts, 2021 - 2033

7.8.3. China

7.8.3.1. Key country dynamics

7.8.3.2. Competitive Scenario

7.8.3.3. Regulatory framework

7.8.3.4. Reimbursement scenario

7.8.3.5. China market estimates and forecasts, 2021 - 2033

7.8.4. South Korea

7.8.4.1. Key country dynamics

7.8.4.2. Competitive Scenario

7.8.4.3. Regulatory framework

7.8.4.4. Reimbursement scenario

7.8.4.5. South Korea market estimates and forecasts, 2021 - 2033

7.8.5. Australia

7.8.5.1. Key country dynamics

7.8.5.2. Competitive Scenario

7.8.5.3. Regulatory framework

7.8.5.4. Reimbursement scenario

7.8.5.5. Australia market estimates and forecasts, 2021 - 2033

7.8.6. Thailand

7.8.6.1. Key country dynamics

7.8.6.2. Competitive Scenario

7.8.6.3. Regulatory framework

7.8.6.4. Reimbursement scenario

7.8.6.5. Thailand market estimates and forecasts, 2021 - 2033

7.9. Latin America

7.9.1. Brazil

7.9.1.1. Key country dynamics

7.9.1.2. Competitive Scenario

7.9.1.3. Regulatory framework

7.9.1.4. Reimbursement scenario

7.9.1.5. Brazil market estimates and forecasts, 2021 - 2033

7.9.2. Mexico

7.9.2.1. Key country dynamics

7.9.2.2. Competitive Scenario

7.9.2.3. Regulatory framework

7.9.2.4. Reimbursement scenario

7.9.2.5. Mexico market estimates and forecasts, 2021 - 2033

7.9.3. Argentina

7.9.3.1. Key country dynamics

7.9.3.2. Competitive Scenario

7.9.3.3. Regulatory framework

7.9.3.4. Reimbursement scenario

7.9.3.5. Argentina market estimates and forecasts, 2021 - 2033

7.10. MEA

7.10.1. South Africa

7.10.1.1. Key country dynamics

7.10.1.2. Competitive Scenario

7.10.1.3. Regulatory framework

7.10.1.4. Reimbursement scenario

7.10.1.5. South Africa market estimates and forecasts, 2021 - 2033

7.10.2. Saudi Arabia

7.10.2.1. Key country dynamics

7.10.2.2. Competitive Scenario

7.10.2.3. Regulatory framework

7.10.2.4. Reimbursement scenario

7.10.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033

7.10.3. UAE

7.10.3.1. Key country dynamics

7.10.3.2. Competitive Scenario

7.10.3.3. Regulatory framework

7.10.3.4. Reimbursement scenario

7.10.3.5. UAE market estimates and forecasts, 2021 - 2033

7.10.4. Kuwait

7.10.4.1. Key country dynamics

7.10.4.2. Competitive Scenario

7.10.4.3. Regulatory framework

7.10.4.4. Reimbursement scenario

7.10.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants

8.2. Company/Competition Categorization

8.2.1. Innovators

8.3. Vendor Landscape

8.3.1. List of key distributors and channel partners

8.3.2. Key customers

8.3.3. Key company market share analysis, 2024

8.3.4. Novo Nordisk A/S

8.3.4.1. Company overview

8.3.4.2. Financial performance

8.3.4.3. Product benchmarking

8.3.4.4. Strategic initiatives

8.3.5. Becton

8.3.5.1. Company overview

8.3.5.2. Financial performance

8.3.5.3. Product benchmarking

8.3.5.4. Strategic initiatives

8.3.6. Dickinson and Company

8.3.6.1. Company overview

8.3.6.2. Financial performance

8.3.6.3. Product benchmarking

8.3.6.4. Strategic initiatives

8.3.7. TERUMO CORPORATION

8.3.7.1. Company overview

8.3.7.2. Financial performance

8.3.7.3. Product benchmarking

8.3.7.4. Strategic initiatives

8.3.8. Owen Mumford Ltd.

8.3.8.1. Company overview

8.3.8.2. Financial performance

8.3.8.3. Product benchmarking

8.3.8.4. Strategic initiatives

8.3.9. Ypsomed

8.3.9.1. Company overview

8.3.9.2. Financial performance

8.3.9.3. Product benchmarking

8.3.9.4. Strategic initiatives

8.3.10. B. Braun Melsungen AG

8.3.10.1. Company overview

8.3.10.2. Financial performance

8.3.10.3. Product benchmarking

8.3.10.4. Strategic initiatives

8.3.11. HTL-STREFA

8.3.11.1. Company overview

8.3.11.2. Financial performance

8.3.11.3. Product benchmarking

8.3.11.4. Strategic initiatives

8.3.12. UltiMed, Inc.

8.3.12.1. Company overview

8.3.12.2. Financial performance

8.3.12.3. Product benchmarking

8.3.12.4. Strategic initiatives

8.3.13. Allison Medical, Inc.

8.3.13.1. Company overview

8.3.13.2. Financial performance

8.3.13.3. Product benchmarking

8.3.13.4. Strategic initiatives

8.3.14. Artsana S.P.a

8.3.14.1. Company overview

8.3.14.2. Financial performance

8.3.14.3. Product benchmarking

 

8.3.14.4. Strategic initiative

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers